Cargando…

Exploring the Potential of Cytomegalovirus-Based Vectors: A Review

Viral vectors have emerged as powerful tools for delivering and expressing foreign genes, playing a pivotal role in gene therapy. Among these vectors, cytomegalovirus (CMV) stands out as a promising viral vector due to its distinctive attributes including large packaging capacity, ability to achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Janine, Jaijyan, Dabbu Kumar, Yang, Shaomin, Pei, Shakai, Tang, Qiyi, Zhu, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612100/
https://www.ncbi.nlm.nih.gov/pubmed/37896820
http://dx.doi.org/10.3390/v15102043
_version_ 1785128627565756416
author Zeng, Janine
Jaijyan, Dabbu Kumar
Yang, Shaomin
Pei, Shakai
Tang, Qiyi
Zhu, Hua
author_facet Zeng, Janine
Jaijyan, Dabbu Kumar
Yang, Shaomin
Pei, Shakai
Tang, Qiyi
Zhu, Hua
author_sort Zeng, Janine
collection PubMed
description Viral vectors have emerged as powerful tools for delivering and expressing foreign genes, playing a pivotal role in gene therapy. Among these vectors, cytomegalovirus (CMV) stands out as a promising viral vector due to its distinctive attributes including large packaging capacity, ability to achieve superinfection, broad host range, capacity to induce CD8+ T cell responses, lack of integration into the host genome, and other qualities that make it an appealing vector candidate. Engineered attenuated CMV strains such as Towne and AD169 that have a ~15 kb genomic DNA deletion caused by virus passage guarantee human safety. CMV’s large genome enables the efficient incorporation of substantial foreign genes as demonstrated by CMV vector-based therapies for SIV, tuberculosis, cancer, malaria, aging, COVID-19, and more. CMV is capable of reinfecting hosts regardless of prior infection or immunity, making it highly suitable for multiple vector administrations. In addition to its broad cellular tropism and sustained high-level gene expression, CMV triggers robust, virus-specific CD8(+) T cell responses, offering a significant advantage as a vaccine vector. To date, successful development and testing of murine CMV (MCMV) and rhesus CMV (RhCMV) vectors in animal models have demonstrated the efficacy of CMV-based vectors. These investigations have explored the potential of CMV vectors for vaccines against HIV, cancer, tuberculosis, malaria, and other infectious pathogens, as well as for other gene therapy applications. Moreover, the generation of single-cycle replication CMV vectors, produced by deleting essential genes, ensures robust safety in an immunocompromised population. The results of these studies emphasize CMV’s effectiveness as a gene delivery vehicle and shed light on the future applications of a CMV vector. While challenges such as production complexities and storage limitations need to be addressed, ongoing efforts to bridge the gap between animal models and human translation continue to fuel the optimism surrounding CMV-based vectors. This review will outline the properties of CMV vectors and discuss their future applications as well as possible limitations.
format Online
Article
Text
id pubmed-10612100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106121002023-10-29 Exploring the Potential of Cytomegalovirus-Based Vectors: A Review Zeng, Janine Jaijyan, Dabbu Kumar Yang, Shaomin Pei, Shakai Tang, Qiyi Zhu, Hua Viruses Review Viral vectors have emerged as powerful tools for delivering and expressing foreign genes, playing a pivotal role in gene therapy. Among these vectors, cytomegalovirus (CMV) stands out as a promising viral vector due to its distinctive attributes including large packaging capacity, ability to achieve superinfection, broad host range, capacity to induce CD8+ T cell responses, lack of integration into the host genome, and other qualities that make it an appealing vector candidate. Engineered attenuated CMV strains such as Towne and AD169 that have a ~15 kb genomic DNA deletion caused by virus passage guarantee human safety. CMV’s large genome enables the efficient incorporation of substantial foreign genes as demonstrated by CMV vector-based therapies for SIV, tuberculosis, cancer, malaria, aging, COVID-19, and more. CMV is capable of reinfecting hosts regardless of prior infection or immunity, making it highly suitable for multiple vector administrations. In addition to its broad cellular tropism and sustained high-level gene expression, CMV triggers robust, virus-specific CD8(+) T cell responses, offering a significant advantage as a vaccine vector. To date, successful development and testing of murine CMV (MCMV) and rhesus CMV (RhCMV) vectors in animal models have demonstrated the efficacy of CMV-based vectors. These investigations have explored the potential of CMV vectors for vaccines against HIV, cancer, tuberculosis, malaria, and other infectious pathogens, as well as for other gene therapy applications. Moreover, the generation of single-cycle replication CMV vectors, produced by deleting essential genes, ensures robust safety in an immunocompromised population. The results of these studies emphasize CMV’s effectiveness as a gene delivery vehicle and shed light on the future applications of a CMV vector. While challenges such as production complexities and storage limitations need to be addressed, ongoing efforts to bridge the gap between animal models and human translation continue to fuel the optimism surrounding CMV-based vectors. This review will outline the properties of CMV vectors and discuss their future applications as well as possible limitations. MDPI 2023-10-02 /pmc/articles/PMC10612100/ /pubmed/37896820 http://dx.doi.org/10.3390/v15102043 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zeng, Janine
Jaijyan, Dabbu Kumar
Yang, Shaomin
Pei, Shakai
Tang, Qiyi
Zhu, Hua
Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title_full Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title_fullStr Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title_full_unstemmed Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title_short Exploring the Potential of Cytomegalovirus-Based Vectors: A Review
title_sort exploring the potential of cytomegalovirus-based vectors: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612100/
https://www.ncbi.nlm.nih.gov/pubmed/37896820
http://dx.doi.org/10.3390/v15102043
work_keys_str_mv AT zengjanine exploringthepotentialofcytomegalovirusbasedvectorsareview
AT jaijyandabbukumar exploringthepotentialofcytomegalovirusbasedvectorsareview
AT yangshaomin exploringthepotentialofcytomegalovirusbasedvectorsareview
AT peishakai exploringthepotentialofcytomegalovirusbasedvectorsareview
AT tangqiyi exploringthepotentialofcytomegalovirusbasedvectorsareview
AT zhuhua exploringthepotentialofcytomegalovirusbasedvectorsareview